Clinical results across multiple solid tumors support the therapeutic potential of NanOlogy LSAM investigational drugs in combination with systemic standard of care therapies for both local and metastatic disease based on sustained tumoricidal response, anti-tumor immunomodulation, and minimal systemic toxicity.